Theravance Biopharma (TBPH) Projected to Post Earnings on Wednesday

Theravance Biopharma (NASDAQ:TBPH) is projected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Theravance Biopharma to post earnings of ($0.05) per share and revenue of $29.90 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Theravance Biopharma Trading Down 4.8 %

NASDAQ:TBPH opened at $8.86 on Tuesday. The stock has a market cap of $435.68 million, a P/E ratio of -8.77 and a beta of 0.21. The stock’s 50-day moving average is $9.38 and its 200-day moving average is $8.90. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $10.90.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.90% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.